Cargando…

Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

BACKGROUND: Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing matur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarze, Julia Katharina, Tijtgat, Jens, Awada, Gil, Cras, Louise, Vasaturo, Angela, Bagnall, Christopher, Forsyth, Ramses, Dufait, Inès, Tuyaerts, Sandra, Van Riet, Ivan, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486335/ https://www.ncbi.nlm.nih.gov/pubmed/36113895 http://dx.doi.org/10.1136/jitc-2022-005141

Ejemplares similares

Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2020)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
por: Monga, Varun, et al.
Publicado: (2021)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021)

Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection
por: Ouaguia, Laurissa, et al.
Publicado: (2019)

Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1(+) Myeloid Dendritic Cells
por: Kalus, Philipp, et al.
Publicado: (2022)

T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment
por: Koster, Bas D, et al.
Publicado: (2021)

Characterization of BDCA1 and BDCA4 dendritic cell subsets in rheumatoid arthritis patients
por: Lebre, MC, et al.
Publicado: (2004)

Paramyxovirus Infection Regulates T Cell Responses by BDCA-1(+) and BDCA-3(+) Myeloid Dendritic Cells
por: Gupta, Meera R., et al.
Publicado: (2014)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

Metabolomic and lipidomic signatures associated with activation of human cDC1 (BDCA3(+)/CD141(+)) dendritic cells
por: Basit, Farhan, et al.
Publicado: (2021)

Differential response of BDCA-1(+) and BDCA-3(+) myeloid dendritic cells to respiratory syncytial virus infection
por: Gupta, Meera R, et al.
Publicado: (2013)

BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
por: Sosa Cuevas, Eleonora, et al.
Publicado: (2020)

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
por: van Ee, Thomas J., et al.
Publicado: (2018)

Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
por: Rodriguez-Ruiz, Maria E, et al.
Publicado: (2023)

Enterovirus-Infected β-Cells Induce Distinct Response Patterns in BDCA1(+) and BDCA3(+) Human Dendritic Cells
por: Schulte, Barbara M., et al.
Publicado: (2015)

Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model
por: Shankara Narayanan, Jayanth S, et al.
Publicado: (2023)

Resident CD141 (BDCA3)(+) dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation
por: Chu, Chung-Ching, et al.
Publicado: (2012)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

Human CD141(+) (BDCA-3)(+) dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
por: Jongbloed, Sarah L., et al.
Publicado: (2010)

The Superior Ability of Human BDCA3(+) (CD141(+)) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells
por: Gu, Fei-fei, et al.
Publicado: (2020)

Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial
por: Gögenur, Mikail, et al.
Publicado: (2023)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors
por: Hoover, Ashley R, et al.
Publicado: (2022)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses
por: Vardeu, Antonella, et al.
Publicado: (2022)

OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models
por: Estrada, Juan, et al.
Publicado: (2023)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject ‘cold’ tumors
por: Semmrich, Monika, et al.
Publicado: (2022)

Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8(+) T-cell functionality
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2020)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
por: Wang, Ruikun, et al.
Publicado: (2022)

PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8(+) T cell-dependent antitumor immunity and abscopal effect after local irradiation
por: Yoon, Yi Na, et al.
Publicado: (2022)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
por: Meyblum, Louis, et al.
Publicado: (2023)

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
por: Beasley, Georgia M, et al.
Publicado: (2021)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ikmcq4ddd9mc7n52llo4c986be